-
Product Name
Tavolixizumab (Synonyms: TAVOLIMAB [USAN]; Tavolimab [WHO-DD])
- Documents
-
Description
Anti-TNFRSF4 / OX40 / CD134 Antibody (Tavolixizumab)
-
Tested applications
ELISA
-
Species reactivity
Human TNFRSF4 / OX40 / CD134
-
Alternative names
TAVOLIMAB [USAN] antibody; Tavolimab [WHO-DD] antibody; tavolimab [INN] antibody; MEDI 0562 [WHO-DD] antibody
-
Isotype
IgG1
-
Preparation
Recombinant expression and purified from CHO cells.
-
Clonality
Monoclonal
-
Formulation
0.1 M Pro-Ac, 20 mM Arg, pH 5.0
-
Storage instructions
-80°C for 2 years under sterile conditions; -20°C for 1 year under sterile conditions; Avoid repeated freeze-thaw cycles.
-
Validations
SDS-PAGE
Anti-TNFRSF4 / OX40 / CD134 Antibody (tavolixizumab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
SEC-HPLC
The purity of Anti-TNFRSF4 / OX40 / CD134 Antibody (tavolixizumab) is 97.98%, determined by SEC-HPLC.
Bioactivity: ELISA
Immobilized human CD134 His at 2 ug/mL can bind Anti-TNFRSF4 / OX40 / CD134 Antibody (tavolixizumab), EC50=0.03236 ug/mL.
Related Products / Services
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"